An expert in gastric cancers describes when and for whom molecular testing should be done in patients with metastatic HER2+ gastric cancer, and which tests are move relevant to treatment decision-making.
Video Programs
John Marshall, MD, reviews the case of a patient with metastatic HER2+ (human epidermal growth factor receptor 2) gastroesophageal junction cancer.
Advertisement
Jamile Shammo, MD, reviews initial treatment options for patients with low risk polycythemia vera.
Dr. Ruben Mesa and panel discuss the importance of and methods for risk assessment in patients with polycythemia vera.
Experts in MPN discuss diagnostic considerations for polycythemia vera.
Prithviraj Bose, MD, reviews the case of a 57-year-old man diagnosed with polycythemia vera.
Advertisement
Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA and EMA Grant Orphan Drug Status to Novel Imaging Drug for Pancreatic Cancer
2
FDA Clears IND of Off-the-Shelf In Vivo CAR-T Therapy for R/R Myeloma
3
FDA Fast-Tracks PARG Inhibitor for mBRCA Platinum-Resistant Ovarian Cancer
4
FDA Pushes Z-Endoxifen Toward Next Step in Breast Cancer Treatment
5